ABBV
Migraine data, but make it investable
AbbVie woke up Friday with a little extra sparkle after Thursday’s Phase 3 LUNA readout for atogepant. The drug hit its primary endpoint and all eight ranked secondary endpoints in menstrual migraine, which is a pretty strong way of saying, “yes, this thing works.”
The key investor takeaway? AbbVie now has a cleaner shot at pushing atogepant deeper into its neuroscience lineup and, eventually, global regulatory filings. In a space where there still isn’t an approved treatment built specifically for menstrual migraine, that’s not just science trivia — it’s commercial optionality.
The business side of the story
AbbVie didn’t stop at the clinical win. The company also confirmed a quarterly cash dividend of $1.73 per share, payable November 16 to shareholders of record as of October 15. That’s the kind of steady cash-return breadcrumb investors love when a pharma name is also trying to prove it can still grow.
And then there’s the Apogee deal: AbbVie said its $10.9 billion cash acquisition of Apogee Therapeutics closed on Sept. 3, adding a late-stage immunology asset and slightly diluting 2026 EPS by 14 cents. Still, management held its full-year 2026 adjusted diluted EPS guide at $13.87 to $14.07, which is basically the corporate version of “we’ve got this.”
Big picture
For shareholders, this is the nice combo meal: a pipeline win, a dividend check, and guidance that didn’t wobble. Not a bad Friday if you’re ABBV.